期刊文献+

IFN-α2b对JAK2V617F突变的骨髓增殖性肿瘤COX-2表达及血管新生的影响 被引量:10

Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms
原文传递
导出
摘要 目的研究干扰素-alpha-2b(IFN-α2b)对骨髓增殖性肿瘤(MPN)患者JAK2激酶、环氧化酶-2(COX-2)及微血管密度的影响及人红白血病HEL细胞系中JAK2V617F与COX-2之间的关系。方法收集在保定市第一医院接受初次治疗的42例有JAK2V617F突变的MPN患者,其中17例患者为IFN-α2b治疗组(给予IFN-α2b肌肉注射治疗),25例为初治组(未行治疗)。另取同期10例特发性免疫性血小板减少性紫癜(ITP)患者作为对照。采用实时荧光定量聚合酶链反应(qRT-PCR)检测MPN患者JAK2V617F/JAK2突变量,免疫组化检测MPN患者和ITP患者骨髓病理组织p-JAK2、COX-2及CD105标记的微血管密度(MVD)。用不同浓度IFN-α2b作用于HEL细胞系,CCK-8检测细胞增殖抑制率,流式细胞术检测凋亡率,Transwell小室检测细胞迁移能力,半定量PCR检测HEL细胞中JAK2、COX-2mRNA表达水平,Western blot检测p-JAK2、COX-2蛋白表达水平。结果初治组患者p-JAK2、COX-2表达水平及MVD高于对照组,IFN-α2b治疗后患者p-JAK2、COX-2及MVD表达水平减低。不同剂量IFN-α2b作用HEL细胞48h,细胞增殖抑制率和细胞凋亡率随其剂量增加逐渐上升,JAK2及COX-2mRNA及p-JAK2、COX-2蛋白表达随其剂量增加逐渐降低。细胞迁移实验结果发现加入0.5×104 U/L IFN-α2b处理HEL细胞24h,迁移至下室的细胞数低于对照组(P<0.05)。结论 IFN-α2b通过调控JAK2信号通路抑制COX-2及MPN患者血管新生。 Objective To investigate the influence of interferon-alpha-2b(IFN-α2b)with JAK2 kinase,COX-2and microvessel density in patients of MPN and the relation of JAK2V617 Fand COX-2in human erythroleukemia cell line(HEL)cells.Methods Forty-two cases of MPN patients with JAK2V617 F mutation of initial treatment were collected from the Frist hospital of Baoding,including the IFN-α2btreatment group with 17 cases and untreated group with 25 cases.10cases of idiopathic immune thrombocytopenic purpura(ITP)patients synchronization were enrolled as controls.JAK2V617F/JAK2 mutation burden of MPN patients was detected by real time PCR(qRTPCR);the expression levels of p-JAK2,COX-2 and microvascular density(MVD) marked with CD105 inpathological tissues of bone marrow in patients of MPN and ITP were detected by immunohistochemistry.The HEL cells were treated with different concentrations of IFN-α2b.The cell proliferation inhibition rate was calculated by CCK-8test;the apoptosis rate was detected by flow cytometry;cell migration ability was tested by transwell chambers.JAK2 and COX-2mRNA were detected by semi-quantitative PCR;p-JAK2 and COX-2protein in HEL cells were detected by Western blotting.Results The expression levels of p-JAK2,COX-2protein and MVD in untreated group were significantly higher than those of control groups.p-JAK2,COX-2and MVD levels were significantly reduced in patients treated with IFN-α2b.Cell growth inhibition rates and apoptosis rates raise up by dose of IFN-α2bin HEL cells at 48 h.The mRNA expression levels of JAK2 and COX-2as well as protein expression levels of p-JAK2 and COX-2had a decreasing tendency with the increase of IFN-α2bconcentration at48 h.The migration capacity level of HEL cells which treated with 0.5×104 U/L IFN-α2bafter 24 hwas lower than that of control group.Conclusion Angiogenesis of MPN and COX-2 were inhibited by IFN-α2bwhich regulates JAK2 signal pathway.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2016年第4期473-478,共6页 Journal of Sichuan University(Medical Sciences)
基金 河北省重点研发科技项目(No.162777120D) 2012年保定市科学技术研究与发展指导计划(No.12ZF105)资助
关键词 干扰素-Α2B 骨髓增殖性肿瘤 微血管密度 HEL细胞系 COX-2 IFN-α2b Myeloproliferative neoplasm Microvascular density HEL cell line COX-2
  • 相关文献

参考文献16

  • 1SONG G,LI Y,JIANG G.Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets.Oncol Reports,2012,28(6):1935-1944.
  • 2LI Y,LI S,SUN D,et al.Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2in non-small cell lung cancer:correlations with angiogenesis and prognosis.Oncol Lett,2014,8(4):1589-1594.
  • 3ABDELAAL AA,AFIFY RA,ZAHER AE,et al.Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia.Hematology,2015,20(9):504-510.
  • 4ZHANG ZR,DUAN YC.Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.Asian Pac J Cancer Prev,2014,15(4):1681-1684.
  • 5MEDINGER M,PASSWEG J.Angiogenesis in myloproliferative neoplasma,new markers and future directions.Memo,2014(7):206-210[2015-10-24].http://dx.doi.org/10.1371/journal.pone.0040531.
  • 6BOVERI E,PASSAMONTI F,RUMI E,et al.Bone marrow microvessel density in chronic myeloproliferative disorders:a study of 115patients with clinicopathological and molecular correlations.Br J Haematol,2008,140(2):162-168.
  • 7成志勇,黄月华,梁文同,王宝艳,王亚丽,孙雪珊,田赫,潘崚.骨髓增殖性肿瘤中JAK2V617F突变与Ⅰ型细胞因子受体相关性研究[J].中国全科医学,2012,15(9):1019-1022. 被引量:12
  • 8WEBER A,BORGHOUTS C,BRENDEL C,et al.Stat5exerts distinct,vital functions in the cytoplasm and nucleus of Bcr-Abl+K562and Jak2(V617F)+HEL leukemia cells.Cancers(Basel),2015,7(1):503-537.
  • 9PARK JH,DARVIN P,LIM EJ,et al.Hwanggeumchal sorghum induces cell cycle arrest,and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts.PLoS One,2012,7(7):e40531[2015-10-24].http://dx.doi.org/10.1371/journal.pone.0040531.
  • 10NEGAARD HF,IVERSEN N,BOWITZ-LOTHE IM,et al.Increased bone marrow microvascular density in haematological malignanciesis associated with differential regulation of angiogenic factors.Leukemia,2009,23(1):162-169.

二级参考文献12

  • 1Kralovics R,Passamonti F,Buser AS. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. N Engl J Med, 2005, 352 (17) :1779 - 1790.
  • 2Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J]. Cancer Cell,2005, 7(4) :387-397.
  • 3Goerttler PS, Steimle C, Marz E. et al. The Jak 2V617F mutation, PRV- 1 overexpression, and EEC formation define a similar cohort of MPD patients [J]. Blood,2005,106(8):2862-2864.
  • 4Shih LY,Lee CT,Ou YC. Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels [J]. Exp Hematol, 1997,25(4):288-292.
  • 5Lacout C, Pisani DF, Tulliez M. et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis [J]. Blood, 2006,108 (5):1652-1660.
  • 6Temerinac S, Klippel S,Strunck E,et al. Cloning of PRV-1 mRNA,a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera[J]. Blood,2000,95(8):2569-2576.
  • 7Vannucchi AM, Guglielmelli P, Antonioli E, et al. Inconsistencies in the association between the JAK2 (V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases [J]. Br J Haematol, 2006,132 (5) : 652 - 654.
  • 8Massaro P ,Foa P ,Pomati M ,et al. Polycythemia vera treated with recombinant interferon-alpha 2α: evidence of a selective effect on the malignant clone [J]. AmJHematol,1997,56(2):126-128.
  • 9Steimle C, Lehmann U, Temerinac S. Biomarker analysis in polycythemia vera under interferon-alpha treatment., clonality, EEC, PRV-1, and JAK 2 V617F [J]. Ann Hematol, 2007,86 (4) :239 -244.
  • 10Lacout C,Pisani DF,Tulliez M. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis[J].Blood,2006,(05):1652-1660.doi:10.1182/blood-2006-02-002030.

共引文献17

同被引文献91

引证文献10

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部